Jefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is bullish on the company’s integrated CRDMO model, strong return ratios and growth prospects, forecasting 18% revenue CAGR through FY29. Key triggers include new commercial molecules and biosimilar launches, while customer concentration and high capex remain key risks.
Jio IPO allotment likely today: GMP signals 22% listing gains — Here’s how to check status
The IPO allotment is expected to be finalised today, allowing applicants to check whether they have been allotted shares through the registrar’s website and other
October 26, 2026